Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?

Davies JC, Alton E, Simbo A, Murphy R, Seth I, Williams K, Somerville M, Jolly L, Morant S, Guest C.

Eur Respir J. 2019 Nov 7;54(5). pii: 1900970. doi: 10.1183/13993003.00970-2019. Print 2019 Nov. No abstract available.

PMID:
31413160
2.

Trained dogs identify people with malaria parasites by their odour.

Guest C, Pinder M, Doggett M, Squires C, Affara M, Kandeh B, Dewhirst S, Morant SV, D'Alessandro U, Logan JG, Lindsay SW.

Lancet Infect Dis. 2019 Jun;19(6):578-580. doi: 10.1016/S1473-3099(19)30220-8. No abstract available.

PMID:
31122774
3.

An Owner-Independent Investigation of Diabetes Alert Dog Performance.

Wilson C, Morant S, Kane S, Pesterfield C, Guest C, Rooney NJ.

Front Vet Sci. 2019 Mar 27;6:91. doi: 10.3389/fvets.2019.00091. eCollection 2019.

4.

How effective are trained dogs at alerting their owners to changes in blood glycaemic levels?: Variations in performance of glycaemia alert dogs.

Rooney NJ, Guest CM, Swanson LCM, Morant SV.

PLoS One. 2019 Jan 15;14(1):e0210092. doi: 10.1371/journal.pone.0210092. eCollection 2019.

5.

Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial.

Faconti L, Mills CE, Govoni V, Gu H, Morant S, Jiang B, Cruickshank JK, Webb AJ.

Br J Clin Pharmacol. 2019 Jan;85(1):169-180. doi: 10.1111/bcp.13783. Epub 2018 Nov 13.

PMID:
30294825
6.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Erratum in: Lancet Diabetes Endocrinol. 2018 Aug;6(8):e16.

7.

Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ; British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY).

J Am Heart Assoc. 2017 Nov 18;6(11). pii: e006986. doi: 10.1161/JAHA.117.006986.

8.

Reducing Arterial Stiffness Independently of Blood Pressure: The VaSera Trial.

Mills CE, Govoni V, Faconti L, Casagrande ML, Morant SV, Webb AJ, Cruickshank JK.

J Am Coll Cardiol. 2017 Sep 26;70(13):1683-1684. doi: 10.1016/j.jacc.2017.07.765. No abstract available.

9.

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.

Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF.

Clin Pharmacol Ther. 2018 Feb;103(2):281-286. doi: 10.1002/cpt.780. Epub 2017 Sep 19.

10.

Serum neurofilament is associated with progression of brain atrophy and disability in early MS.

Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli Ö, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S.

Neurology. 2017 Feb 28;88(9):826-831. doi: 10.1212/WNL.0000000000003653. Epub 2017 Feb 1.

11.

Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.

Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM.

Br J Clin Pharmacol. 2017 Jun;83(6):1298-1308. doi: 10.1111/bcp.13205. Epub 2017 Jan 23.

12.

Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM.

Br J Clin Pharmacol. 2017 Mar;83(3):653-663. doi: 10.1111/bcp.13152. Epub 2016 Nov 12.

13.

PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.

Williams B, MacDonald TM, Morant SV, Brown MJ.

Lancet. 2016 Apr 2;387(10026):1373-1374. doi: 10.1016/S0140-6736(16)00698-X. No abstract available.

PMID:
27115814
14.

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group.

Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18.

15.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group.

Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.

16.

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.

Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951.

17.

Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension.

Brown MJ, Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I.

BMJ Open. 2015 Aug 7;5(8):e008086. doi: 10.1136/bmjopen-2015-008086.

18.

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.

MacDonald TM, Williams B, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Mackenzie IS, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e007645. doi: 10.1136/bmjopen-2015-007645.

19.

Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database.

Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J.

J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):76-84. doi: 10.1136/jnnp-2013-305450. Epub 2013 Sep 19.

20.

Investigation into the value of trained glycaemia alert dogs to clients with type I diabetes.

Rooney NJ, Morant S, Guest C.

PLoS One. 2013 Aug 7;8(8):e69921. doi: 10.1371/journal.pone.0069921. eCollection 2013.

21.

Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.

Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G.

PLoS One. 2013 Aug 1;8(8):e70019. doi: 10.1371/journal.pone.0070019. Print 2013.

22.

An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population.

Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ.

BMC Fam Pract. 2013 Feb 26;14:28. doi: 10.1186/1471-2296-14-28.

23.

Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.

Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L.

BMJ. 2012 Jul 13;345:e4447. doi: 10.1136/bmj.e4447.

24.

A predictive model of hospitalisation and death from chronic obstructive pulmonary disease.

Schembri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D, MacDonald TM, Winter JH.

Respir Med. 2009 Oct;103(10):1461-7. doi: 10.1016/j.rmed.2009.04.021. Epub 2009 Jun 9.

25.

Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD.

Schembri S, Morant S, Winter JH, MacDonald TM.

Thorax. 2009 Jul;64(7):567-72. doi: 10.1136/thx.2008.106286. Epub 2009 Mar 24.

PMID:
19321465
26.

Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms.

Morant S, Bloomfield G, Vats V, Chapple C.

J Sex Med. 2009 Apr;6(4):1103-1110. doi: 10.1111/j.1743-6109.2008.01120.x. Epub 2008 Dec 5.

PMID:
19138377
27.

Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK.

Morant SV, Reilly K, Bloomfield GA, Chapple C.

Int J Clin Pract. 2008 May;62(5):688-94. doi: 10.1111/j.1742-1241.2008.01737.x. Epub 2008 Mar 17.

PMID:
18355237
28.

Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.

MacDonald TM, Morant SV.

Br J Clin Pharmacol. 2008 May;65(5):775-86. doi: 10.1111/j.1365-2125.2007.03072.x. Epub 2008 Feb 14.

29.

Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care.

MacDonald TM, Morant SV, Mozaffari E.

Curr Med Res Opin. 2007 Nov;23(11):2765-74.

PMID:
17919356
30.
31.

Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.

Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S.

BJU Int. 2007 Apr;99(4):860-3.

32.

Application of a propensity score to adjust for channelling bias with NSAIDs.

Morant SV, Pettitt D, MacDonald TM, Burke TA, Goldstein JL.

Pharmacoepidemiol Drug Saf. 2004 Jun;13(6):345-53.

PMID:
15170763
33.

Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

Morant SV, McMahon AD, Cleland JG, Davey PG, MacDonald TM.

Br J Clin Pharmacol. 2004 Feb;57(2):188-98.

34.

Rates of production of acetate, propionate, and butyrate in the rumen of lactating dairy cows given normal and low-roughage diets.

Sutton JD, Dhanoa MS, Morant SV, France J, Napper DJ, Schuller E.

J Dairy Sci. 2003 Nov;86(11):3620-33.

36.

A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.

Morant SV, Shield MJ, Davey PG, MacDonald TM.

Pharmacoepidemiol Drug Saf. 2002 Jul-Aug;11(5):393-400.

PMID:
12271881
37.

A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.

Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, Luta G, Callahan LF, Wang X, Schwartz T, Abramson SB, Caldwell JR, Harrell RA, Kremer JM, Lautzenheiser RL, Markenson JA, Schnitzer TJ, Weaver A, Cummins P, Wilson A, Morant S, Fort J.

Arthritis Rheum. 2001 Jul;44(7):1587-98.

38.

Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury.

Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ.

Aliment Pharmacol Ther. 2000 May;14(5):529-34.

39.

Gastrointestinal complications and meloxicam.

Fenn GC, Morant SV, Shield MJ.

Br J Rheumatol. 1997 Nov;36(11):1234. No abstract available.

PMID:
9402874
40.

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study.

MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG.

BMJ. 1997 Nov 22;315(7119):1333-7.

41.

Safety of meloxicam: a global analysis of clinical trials [British Journal of Rheumatology, 1996;35(suppl. 1):68-77].

Fenn GC, Morant SV.

Br J Rheumatol. 1997 Jul;36(7):817-9. No abstract available.

PMID:
9255122
42.

Emergency admissions for upper gastrointestinal disease and their relation to NSAID use.

Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, Bardhan KD.

Aliment Pharmacol Ther. 1997 Apr;11(2):283-91.

43.

Evaluation of intravenous tramadol for use in the prehospital situation by ambulance paramedics.

Ward ME, Radburn J, Morant S.

Prehosp Disaster Med. 1997 Apr-Jun;12(2):158-62.

PMID:
10187002
44.

Misoprostol in patients taking non-steroidal anti-inflammatory drugs. Analysis excluded in important events.

Shield MJ, Morant SV.

BMJ. 1996 Mar 30;312(7034):846; author reply 847. No abstract available.

45.

Arthrotec, diclofenac and ibuprofen in general practice.

Kiff PS, Stead H, Morant SV, Shield MJ.

Eur J Rheumatol Inflamm. 1994;14(3 Suppl):31-8. No abstract available.

PMID:
7556344
46.

The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol.

Bardhan KD, Bjarnason I, Scott DL, Griffin WM, Fenn GC, Shield MJ, Morant SV.

Br J Rheumatol. 1993 Nov;32(11):990-5.

PMID:
8220939
47.
48.

Consequences of diagnostic errors in mastitis therapy trials.

Morant SV, Dodd FH, Natzke RP.

J Dairy Res. 1988 Aug;55(3):315-29.

PMID:
3216055
49.

An in-line sampling technique to measure the bacterial contamination of milk during milking.

McKinnon CH, Bramley AJ, Morant SV.

J Dairy Res. 1988 Feb;55(1):33-40.

PMID:
3385065

Supplemental Content

Loading ...
Support Center